Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Intestinal enterocyte villus mannose residues are high-mannose glycans located on the apical surface of intestinal epithelial cells. These carbohydrate structures serve as critical attachment points for various pathogens, most notably Adherent-Invasive Escherichia coli (AIEC) and Uropathogenic Escherichia coli (UPEC), which utilize the FimH adhesin to bind to these residues [1, 2]. This interaction facilitates bacterial colonization, invasion of the gut wall, and the subsequent inflammatory cascade characteristic of diseases like Crohn's disease [3, 10]. In pharmacological contexts, these residues are targeted by anti-adhesive agents such as Sibofimloc (EB8018) or D-mannose, which act as competitive inhibitors to block bacterial binding [5, 11]. By preventing the attachment of pro-inflammatory bacteria to the intestinal lining, these therapies aim to reduce mucosal inflammation and maintain gut homeostasis without disrupting the commensal microbiome [6, 8].
Competitive inhibition of bacterial adhesin (FimH) binding to host cell surface mannose residues, preventing bacterial colonization and invasion.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Intestinal enterocyte villus mannose residues.